Novo Nordisk’s new Wegovy weight loss pill is attracting a large share of patients who have never taken a GLP-1 drug before, according to early real world data from health analytics firm Truveta. Among initial users of the oral formulation, 36 percent had no prior experience with a GLP-1 medicine, suggesting the pill is expanding the market rather than simply pulling patients away from injectable options.
The once daily tablet, approved in the United States on December 22 for chronic weight management, is the first oral GLP-1 therapy cleared specifically for this indication. Truveta reviewed health records from 8,762 US patients with evidence of a prescription written or filled for the new Wegovy pill, offering an early snapshot of who is taking it in the first weeks after launch.
The analysis found that 21.1 percent of patients starting the pill had previously used the injectable version of Wegovy, while 15.8 percent switched from Eli Lilly’s Zepbound, another injectable GLP-1 drug. That mix indicates some migration from established injectable products but also a sizeable cohort coming to the class for the first time, a pattern that investors and analysts have been watching closely.
Early adopters of the oral drug have a distinct demographic profile. In the first six weeks on the market, 73.3 percent of patients with prescriptions were female, 72.8 percent were white and 71.6 percent lived in urban areas. Age-wise, 34 percent were between 45 and 59 years, and 37.8 percent were 60 years or older, pointing to uptake in middle-aged and older adults who may be managing long standing weight and metabolic risks.
Truveta cautioned that these patterns are likely to shift as access broadens and more clinicians become comfortable prescribing the pill. Some patients currently on injectable GLP 1 therapies may also move to the oral version once they complete their existing courses, which could increase the share of switchers over time. A rival oral weight loss drug from Lilly is expected to secure US approval around April, adding another option in a fast growing category.
Novo Nordisk has priced lower doses of the daily Wegovy pill at 149 dollars per month for self paying patients in the US, with that figure set to rise to 199 dollars from April. Out of pocket cost, insurance coverage and prescriber preference are all expected to shape how quickly the oral format scales relative to injectable pens, which have already seen rapid growth.
Truveta’s findings come against the backdrop of surging demand for GLP 1 therapies in general. In a separate report released in January, the company noted that prescriptions for GLP 1 drugs now account for more than 7 percent of all prescriptions nationwide in the US, underscoring how quickly the class has moved from diabetes care into mainstream obesity treatment. The arrival of the Wegovy pill appears set to deepen that trend by drawing in patients and clinicians who prefer tablets over injections.
